Non-small cell lung cancer
Conditions
Interventions
Sintilimab in combination with bevacizumab and chemotherapy groups:None
PD-1/PD-L1 inhibitor combination chemotherapy group:None
Bevacizumab combination chemotherapy group:None
Platinum-containing two-drug chemotherapy group:None
Three-generation EGFR-TKI drug dosing group:None
Third-generation EGFR-TKI drugs in combination with other drug groups:None
Sponsors
Zhengzhou Third People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Inoperable incurable locally advanced and metastatic non-squamous NSCLC (AJCC 8th edition is Phase III.B, III.C, IV.); 2) Histopathological or cytological confirmation of positive EGFR gene mutation; 3) Failure of targeted therapy with EGFR-TKI.
Exclusion criteria
Exclusion criteria: 1) For the retrospective portion of the study, patients with NSCLC without efficacy assessment; 2) Patients who have been treated with a dosing regimen other than those specified for inclusion in this study, such as anilotinib, or drugs other than EGFR-TKIs analogs, prior to inclusion in this study; 3) Patients with NSCLC with EGFR wild-type; 4) NSCLC patients with histologic classification of squamous carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Overall survival;Progression-free survival;Duration of relief; | — |
Countries
China
Contacts
Public ContactKong Tiandong
Zhengzhou Third People's Hospital
Outcome results
None listed